STATISTICS FOR SECONDARY STUDY OBJECTIVES Sample Clauses

STATISTICS FOR SECONDARY STUDY OBJECTIVES. SECONDARY OBJECTIVE 1: Test the hypothesis that, on average over the study period, patients' PSA values will trend downward compared to screening values. Each subject is assayed eight times at various times between day 1 and week 26. Regression analysis using Generalized Estimating Equations (GEE) is used to test for trend of improvement over the study period. 38 SECONDARY OBJECTIVE 2: Describe how the patient's experiences of pain, physical functioning and quality-of-life measures change during the course of treatment and during the follow-up period. For each patient over the study period pain is assessed five times using the Brief Pain Inventory, physical functioning is measured six times using both the Karnofsky and Zub▇▇▇ ▇▇rformance Scales, and quality of life assessments are obtained five times using the FACT-P questionnaire. Patient averages at screening and during the study weeks is graphed and the trends and tempos of these repeated measurements is modeled and analyzed using GEE. SECONDARY OBJECTIVE 3: Describe how the patient's skin test and other lab results change during the course of treatment and during the follow-up period. For each patient over the study period skin tests are assessed four times using four recall antigens (Candida, Mumps, and PPD) and CBC, differential blood chemistry and serum markers are measured nine times. Patient averages at screening and during the study weeks are graphed and the trends of these repeated measurements are modeled and analyzed using GEE.
View SourceView Similar (2)
STATISTICS FOR SECONDARY STUDY OBJECTIVES. SECONDARY OBJECTIVE 1: Test the hypothesis that, on average over the study period, patients' PSA values will trend downward compared to screening values. Each subject is assayed eight times at various times between day 1 and week 26. Regression analysis using Generalized Estimating Equations (GEE) is used to test for trend of improvement over the study period. SECONDARY OBJECTIVE 2: Describe how the patient's experiences of pain, physical functioning and quality-of-life measures change during the course of treatment and during the follow-up period. For each patient over the study period pain is assessed five times using the Brief Pain Inventory, physical functioning is measured six times using both the Karnofsky and Zub▇▇▇ Performance Scales, and quality of life assessments are obtained five times using the FACT-P questionnaire. Patient averages at screening and during the study weeks is graphed and the trends and tempos of these repeated measurements is modeled and analyzed using GEE. SECONDARY OBJECTIVE 3: Describe how the patient's skin test and other lab results change during the course of treatment and during the follow-up period. For each patient over the study period skin tests are assessed four times using four recall antigens (Candida, Mumps, PPD, and rPSMA) and CBC, differential blood chemistry and serum markers are measured nine times. Patient averages at screening and during the study weeks are graphed and the trends of these repeated measurements are modeled and analyzed using GEE. 101 November 16, 1999 Page 24
View Source

Related to STATISTICS FOR SECONDARY STUDY OBJECTIVES

  • Benchmarks for Measuring Accessibility For the purposes of this Agreement, the accessibility of online content and functionality will be measured according to the W3C’s Web Content Accessibility Guidelines (WCAG) 2.0 Level AA and the Web Accessibility Initiative Accessible Rich Internet Applications Suite (WAI-ARIA) 1.0 for web content, which are incorporated by reference.

  • Evaluation Criteria 5.2.1. The responses will be evaluated based on the following: (edit evaluation criteria below as appropriate for your project)

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving (either itself or through the acts of a SUBLICENSEE) the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Statistical, Demographic or Market-Related Data All statistical, demographic or market-related data included in the Registration Statement, the Disclosure Package or the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate and all such data included in the Registration Statement, the Disclosure Package or the Prospectus accurately reflects the materials upon which it is based or from which it was derived.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.